Compare SNOA & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | NVNO |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.1M |
| IPO Year | 2006 | 2017 |
| Metric | SNOA | NVNO |
|---|---|---|
| Price | $1.26 | $8.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.1K | 20.0K |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,529,000.00 | $31,243.00 |
| Revenue This Year | $22.44 | N/A |
| Revenue Next Year | $12.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.68 | N/A |
| 52 Week Low | $0.85 | $0.30 |
| 52 Week High | $4.60 | $13.44 |
| Indicator | SNOA | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 44.18 |
| Support Level | $1.25 | $8.84 |
| Resistance Level | $1.34 | $11.47 |
| Average True Range (ATR) | 0.05 | 0.62 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 71.43 | 60.12 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.